BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

IDM Pharma, Inc. 

5820 Nancy Ridge Drive

San Diego  California  92121  U.S.A.
Phone: 858-860-2500 Fax: 858-860-2600


SEARCH JOBS










 Company News
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Completes Acquisition of IDM Pharma, Inc. (IDMI) 6/25/2009 9:50:55 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announces Completion of Tender Offer for All Outstanding Shares of IDM Pharma, Inc. (IDMI) 6/23/2009 9:34:04 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) to Acquire IDM Pharma, Inc. (IDMI) for $75 Million, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 5/18/2009 7:35:11 AM
IDM Pharma, Inc. (IDMI) Reports First Quarter Financial Results 5/11/2009 8:24:17 AM
IDM Pharma, Inc. (IDMI) Receives The Nasdaq Stock Market -- New York Shareholder Equity Notification 4/14/2009 8:51:15 AM
IDM Pharma, Inc. (IDMI) Complies With NASDAQ Marketplace Rule 4350(b)(1)(B) and Announces Filing of Annual Report on Form 10-K for 2008 Fiscal Year Containing Audit Opinion With Going Concern Qualification 4/3/2009 8:29:46 AM
IDM Pharma, Inc. (IDMI) Reports 2008 Financial Results 3/31/2009 9:15:14 AM
IDM Pharma, Inc. (IDMI)'s MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3/9/2009 10:17:12 AM
IDM Pharma, Inc. (IDMI) Provides Update on Mifamurtide (MEPACT(R), L-MTP-PE) European Regulatory Status Positive Opinion Formally Adopted by CHMP 12/19/2008 10:37:07 AM
IDM Pharma, Inc. (IDMI) Receives Recommendation for Approval of Mifamurtide for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use 11/18/2008 6:18:20 AM
123456789